Brazil temporarily suspended the dengue vaccination campaign it began in January, after detecting two deaths and several cases of serious adverse reactions. The vaccine, the world’s first single-dose shot, was developed by the Butantan Institute in São Paulo and had already been given to half a million people through the public health system. Health authorities stressed that there is not yet enough data to link the deaths to the product and that the interruption is a preventive measure.
